Nilotinib Mylan

Nilotinib, the active ingredient in Nilotinib Mylan, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It selectively blocks the BCR‑ABL enzyme, thereby treating chronic myeloid leukemia in the chronic phase and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Nilotinib Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable access to high‑quality oncology medicines.

Nilotinib is indicated for hematologic malignancies driven by the BCR‑ABL tyrosine kinase. - Chronic myeloid leukemia (CML): reduces disease progression and improves survival in patients in the chronic phase. - CML (accelerated or blast phase): offers a therapeutic option when resistance to prior tyrosine‑kinase inhibitors occurs. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission induction in adult patients.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, often transient. - Rash: skin erythema or pruritus. - Fatigue: generalized tiredness. - Headache: mild to moderate intensity. - Myalgia: muscle aches.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias. - Pancreatitis: inflammation of the pancreas, presenting with abdominal pain. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Severe neutropenia: marked reduction in neutrophil count. - Severe thrombocytopenia: low platelet levels increasing bleeding risk. - Anaphylactic reactions: rare but potentially life‑threatening hypersensitivity.

Before initiating therapy, clinicians should assess several safety parameters. - Cardiac monitoring: obtain baseline ECG and periodically evaluate QT interval. - Hepatic function: monitor liver enzymes regularly during treatment. - Pancreatic enzymes: check amylase and lipase to detect pancreatitis early. - Pregnancy: avoid use; safety in pregnancy and lactation is unknown. - Drug interactions: review concomitant QT‑prolonging or CYP3A4‑modulating agents. - Store below 25°C: keep in the original pack, protect from moisture.

Nilotinib has a notable interaction profile that requires careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Nilotinib exposure. - QT‑prolonging drugs (e.g., amiodarone, sotalol): additive risk of cardiac arrhythmias. - Antacids containing aluminum or magnesium: can reduce absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower Nilotinib levels. - Warfarin: potential alteration of anticoagulant effect, requiring INR monitoring. - Statins metabolized by CYP3A4 (e.g., simvastatin): increased risk of statin‑related toxicity. - Diuretics causing electrolyte imbalance: may exacerbate QT prolongation.